RxDoctor Payments Data

Cherise Hunter

Nurse Practitioner · Rapid City, SDNPI 1528361581

Payments from drug & device makers

$315in general payments, 2019–2025

Across 12 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$99
  • Pfizer$54
  • Johnson & Johnson$47
  • Merck$38
  • Gilead$28
  • Bristol Myers Squibb$18
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$16653%
  • Education$14947%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$315 in reported general payments places this provider in the 60th percentile of 504 nurse practitioner providers in South Dakota.

See all nurse practitioner providers in South Dakota

Medicare billing

Part B allowed, 2024
$45,942
Medicare patients
405
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide60$1,120,037
XtandiEnzalutamide56$758,519
ImbruvicaIbrutinib37$503,703
Lenalidomide28$425,256
PomalystPomalidomide19$372,335
CalquenceAcalabrutinib Maleate23$305,708
JakafiRuxolitinib Phosphate18$284,543
NubeqaDarolutamide22$255,995
BrukinsaZanubrutinib14$202,625
VenclextaVenetoclax14$50,182
Abiraterone Acetate24$49,816
EliquisApixaban34$19,059
XareltoRivaroxaban13$6,961
CreonLipase/Protease/Amylase14$6,580
Exemestane21$5,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$18$1,120,03760 claims
Astellas Pharma US IncXtandi$99$758,51956 claims
PfizerEliquis$54$19,05934 claims
Johnson & JohnsonXarelto$47$6,96113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 504 nurse practitioner providers in South Dakota.

Other nurse practitioner in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →